ArticleJournal of advanced pharmaceutical technology & research
Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Prevalence, predictors, and clinical relevance of drug-drug interactions in outpatient prescribing: A national cross-sectional study.PloS one · 2026Article
- The Treatment of Psychotic and Bipolar Disorders Within the South African Context: Perspectives of a Clinical Pharmacist.Healthcare (Basel, Switzerland) · 2025Article
- Insufficient correctness of package inserts for psychotropic drugs in Germany.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Evaluation of potentially significant drug-drug interactions among patients receiving psychotropic medications: A real-world retrospective study.Qatar medical journal · 2025Article
- From prescription patterns to drug safety: a closer look at non-steroidal anti-inflammatory drugs and analgesics in outpatient pharmacy.Frontiers in pharmacology · 2025Article
- Evaluation of drug interactions in outpatients taking antipsychotic medications.Frontiers in pharmacology · 2025Article
- Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Factors associated with potential drug-drug interactions in psychiatric inpatients.European journal of hospital pharmacy : science and practice · 2024Article
- Prescribing pattern of antipsychotics for patients with schizophrenia using the total daily dose online tool.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021.Medicina (Kaunas, Lithuania) · 2023Observational
- Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS).Frontiers in psychology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of the antipsychotic drugs are also known to interact with other co-administered drugs. Drug-drug interaction (DDI) reports among patients receiving antipsychotic medications are common. The study aims to identify the potential drug-drug, drug-tobacco, and drug-ethanol interactions associated with antipsychotics and significant predictors of potential DDIs (pDDIs). A prospective observational study was conducted among psychiatric inpatients receiving antipsychotic therapy and met the inclusion criteria that were reviewed for the presence of pDDIs using DRUGDEX-Micromedex database 2.0. The identified pDDIs were graded according to the severity and type of documentation. A total of 110 patients had a minimum of a single interaction, and the overall frequency of pDDIs reported was 64.7%. Of 158 pDDIs, 92 interactions (58.2%) were of major severity, while 66 interactions were of moderate severity (41.8%). Olanzapine with valproate (40 [25.3%]) was the most commonly documented pDDIs, followed by risperidone with valproate (20 [12.6%]). Olanzapine with tobacco (20 [69%]) was the most common drug-tobacco interaction. Simultaneously, olanzapine with ethanol was the most common potential drug and ethanol interaction (9 [50%]). Variables such as the number of drugs and polypharmacy statistically significantly predicted pDDIs (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.